New class of drugs may help tackle resistant cancers


Team Udayavani, Apr 12, 2018, 3:00 PM IST

London: Researchers have discovered a new class of drugs that could help treat cancer patients who no longer respond to existing therapies. The drug may not become available to patients for a number of years yet, but researchers at Imperial College London in the UK believe that if clinical trials are successful, it could be used to tackle a variety of treatment-resistant cancers.

Patients with breast cancer for example frequently become resistant to existing hormone-based treatments, leading to the disease becoming fatal. Early lab-based tests of ICEC0942 were successful in targeting resistant breast cancers and indicated minimal side effects, according to the results published in the journal Molecular Cancer Therapeutics.

ICEC0942 was then licenced to Carrick Therapeutics, who developed it into a molecule named CT7001, which they have taken to early-stage clinical trials in less than two years. “Treatment-resistant tumours represent a significant threat for patients, as once cancer stops responding to treatments there is increasingly little clinicians can do,” said Charles Coombes, a professor at Imperial College London.

“Drugs such as these could help to shift the balance back in favour of the patients, potentially providing a new option to patients for who existing treatments no longer work,” said Coombes. The drug targets an enzyme called CDK7, involved in directing cells through their life-cycle, which consists of growth, DNA replication and cell division.

CDK7 is also involved in the process of transcription, a vital step in gene expression – the creation of proteins to carry out cell functions. Particular cancers, such as treatment-resistant breast cancers, have a unique dependence on transcription, meaning targeting CDK7 may be particularly effective.

By inhibiting transcription, ICEC0942 shuts down the ability of the cancer to spread. As well as breast cancers, cancers such as acute myeloid leukaemia and small-cell lung cancer are particularly transcription-dependent, so ICEC0942 may work well for these too, especially where they have become resistant to other treatments.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Nagarjuna’s younger son Akhil Akkineni engaged

People getting heartburns after I became CM for second time: Siddaramaiah

Newborn baby kidnapped from Kalaburagi hospital in Karnataka

Gukesh draws with Liren in second game of World Chess Championship

All about ‘One Nation One Subscription’ scheme

PAN cards with QR code planned under PAN 2.0 project

2nd Test: Will Rohit agree to bat in middle-order and let Rahul open?

Related Articles More

Genetic vulnerability for low insulin, unhealthy fat major causes for diabetes in South Asians: Study

Study links overthinking to ‘constant communication’ between brain’s fear-centre, social behaviour

Mangaluru: Campco opposes WHO’s claim of arecanut being carcinogenic

10 month baby gets new heart, new life

World COPD Day: Know your lung function

MUST WATCH

Grafting

Coconut Flower

Prakash Belawadi

Naxal Leader Vikram Gowda

Christmas Cake Fruit Mixing


Latest Additions

CAMPCO urges Centre to take action on areca nut ‘carcinogen classification’

Nagarjuna’s younger son Akhil Akkineni engaged

Kerala CM accuses Centre of turning ‘blind-eye’ towards Wayanad’s need for help

Renukaswamy Murder Case: High Court defers hearing on Darshan’s bail plea to Nov 28

People getting heartburns after I became CM for second time: Siddaramaiah

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.